KR-32560

Subscribe to Selected New Research on KR-32560

1 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: sodium/hydrogen exchanger-1 inhibitor with anti-platelet activity

Also Known As:

(5-(2-methoxy-5-fluorophenyl)furan-2-ylcarbonyl)guanidine

Bio-Agent Context: Research Results

Organic Chemicals: 40

Amidines: 8

Guanidines: 11

KR-32560: 1

Related Diseases

1.	Ventricular Tachycardia 08/01/2005 - "KR-32560 dose-dependently reduced the total number of ventricular premature beats (VPBs) during ischemia from 510.2 (control) to 353.8 and 134.2 beats (all P<0.05, n = 6), while reducing ventricular tachycardia (VT) incidence from 49.3 (control) to 26.8 and 4.3 and VT duration from 249.2 s (control) to 150.5 and 26.7 s (all P<0.05, n = 6)" Get all the results and reference details, order at left...
2.	Ventricular Fibrillation 08/01/2005 - "KR-32560 dose-dependently reduced ventricular fibrillation (VF) incidence from 19.0 (control) to 9.2 and 1.2 and VF duration from 88.0 s to 34.5 and 2.8 s (all P<0.05, n = 6)" Get all the results and reference details, order at left...
3.	Ischemia 08/01/2005 - "KR-32560 at 0.1 and 1.0 mg/kg (i.v. bolus, given 10 min before ischemia) reduced infarct size from 65.9% (control) to 49.7% and 32.7%, respectively, while reducing the extension of myocardial injury (mm(3)/g of left heart weight) from 405.1 (control) to 302.9 and 185.4, respectively (all P<0.05 vs control)" 08/01/2005 - "These results indicate that KR-32560 may exert significant cardioprotective effects in ischemia/reperfusion heart injury." 08/01/2005 - "KR-32560 dose-dependently reduced the total number of ventricular premature beats (VPBs) during ischemia from 510.2 (control) to 353.8 and 134.2 beats (all P<0.05, n = 6), while reducing ventricular tachycardia (VT) incidence from 49.3 (control) to 26.8 and 4.3 and VT duration from 249.2 s (control) to 150.5 and 26.7 s (all P<0.05, n = 6)" 08/01/2005 - "The cardioprotective effects of the novel sodium/hydrogen exchanger-1 (NHE-1) inhibitor KR-32560 {[5-(2-methoxy-5-fluorophenyl)furan-2-ylcarbonyl]guanidine} were studied in an anesthetized rat model of 30-min ischemia / 2.5-h reperfusion heart injury" Get all the results and reference details, order at left...
4.	Heart Injuries 08/01/2005 - "These results indicate that KR-32560 may exert significant cardioprotective effects in ischemia/reperfusion heart injury." 08/01/2005 - "The cardioprotective effects of the novel sodium/hydrogen exchanger-1 (NHE-1) inhibitor KR-32560 {[5-(2-methoxy-5-fluorophenyl)furan-2-ylcarbonyl]guanidine} were studied in an anesthetized rat model of 30-min ischemia / 2.5-h reperfusion heart injury" Get all the results and reference details, order at left...
5.	Premature Cardiac Complexes (Extrasystoles) 08/01/2005 - "KR-32560 dose-dependently reduced the total number of ventricular premature beats (VPBs) during ischemia from 510.2 (control) to 353.8 and 134.2 beats (all P<0.05, n = 6), while reducing ventricular tachycardia (VT) incidence from 49.3 (control) to 26.8 and 4.3 and VT duration from 249.2 s (control) to 150.5 and 26.7 s (all P<0.05, n = 6)" Get all the results and reference details, order at left...
5 Diseases and 1 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Guanidine (Guanidine Nitrate)
2.	Sodium
3.	Hydrogen
4.	furan
4 Drugs and Important Bio-Agents and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>